X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-harmful-reactions-fake-botox-injections-2024-04-16/
https://www.reuters.com/legal/us-justice-department-files-complaint-against-regeneron-alleges-fraudulent-drug-2024-04-10/
https://www.bayer.com/media/en-us/bayer-pharmaceuticals-advances-next-generation-of-blockbuster-medicines/
https://www.bayer.com/media/en-us/aflibercept-8-mg-clinical-study-data-now-published-in-the-lancet/
https://www.globenewswire.com/news-release/2024/03/08/2843031/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Pivotal-Data-in-Wet-Age-related-Macular-Degeneration-wAMD-and-Diabetic-Macular-Edema-DME-Published-in-The-Lancet.html
https://www.fiercepharma.com/pharma/regenerons-eylea-hd-vs-roches-vabysmo-will-real-soc-please-stand
https://www.globenewswire.com//news-release/2024/01/03/2803065/0/en/Alvotech-Clinical-Study-Results-Demonstrate-Therapeutic-Equivalence-between-Biosimilar-Candidate-AVT06-and-Reference-Product-Eylea-aflibercept.html
https://www.bloomberg.com/news/articles/2023-12-27/regeneron-gains-after-eye-drug-patent-victory-over-viatris
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761355
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125418
https://www.indianpharmapost.com/news/biocon-biologics-receives-mhra-uk-approval-for-biosimilar-aflibercept-yesafili-14894
https://www.bayer.com/media/en-us/bayers-aflibercept-8-mg-recommended-for-approval-in-eu/
https://www.fiercepharma.com/pharma/regeneron-touts-launch-high-dose-eylea-battle-roches-vabysmo
https://www.globenewswire.com//news-release/2023/11/01/2771661/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Data-Presentations-at-AAO-Reinforce-Efficacy-and-Safety-Profile-in-Wet-Age-related-Macular-Degeneration-and-Diabetic-Macular-Edema.html
https://www.globenewswire.com//news-release/2023/10/05/2755506/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Two-year-Results-from-Pivotal-PULSAR-Trial-in-Wet-Age-related-Macular-Degeneration-Presented-at-EURETINA.html
https://www.bayer.com/media/en-us/bayer-to-present-new-aflibercept-8-mg-60-week-and-96-week-data-for-patients-with-neovascular-wet-age-related-macular-degeneration-and-diabetic-macular-edema/
https://www.fiercebiotech.com/biotech/unity-gathers-around-diabetic-macular-edema-retina-therapy-middles-mid-stage-wet-amd-test
https://www.globenewswire.com//news-release/2023/09/26/2749929/32452/en/Adverum-Biotechnologies-Announces-Positive-Aflibercept-Protein-Level-Data-from-the-LUNA-Phase-2-Trial.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761355
https://www.fiercepharma.com/pharma/novartis-says-biosimilar-matches-eylea-another-threat-regenerons-eye-disease-blockbuster
https://www.bayer.com/media/en-us/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years/
https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-pharma-beats-quarterly-profit-estimates-2023-08-03/
https://investor.regeneron.com/news-releases/news-release-details/aflibercept-8-mg-two-year-results-pivotal-photon-trial-diabetic
https://www.prnewswire.com/news-releases/biocon-biologics-announces-positive-chmp-opinion-for-yesafili-biosimilar-aflibercept-301883594.html
https://endpts.com/fda-cites-cleaning-maintenance-issues-at-catalent-facility-responsible-for-eylea-rejection/
https://www.cnbc.com/2023/06/27/regeneron-shares-fall-after-fda-rejects-eye-disease-treatment.html
https://www.globenewswire.com/news-release/2023/06/27/2695733/0/en/Two-year-Results-for-Aflibercept-8-mg-from-Pivotal-PHOTON-Trial-Demonstrate-Durable-Vision-Gains-at-Extended-Dosing-Intervals-in-Diabetic-Macular-Edema.html
https://www.globenewswire.com/news-release/2023/06/27/2695732/0/en/FDA-Issues-Complete-Response-Letter-CRL-for-Aflibercept-8-mg-Biologics-License-Application-Solely-Due-to-an-Ongoing-Review-of-Inspection-Findings-at-a-Third-party-Filler.html
https://seekingalpha.com/article/4611302-regeneron-solid-investment-based-on-continued-eylea-expansion
https://www.globenewswire.com/news-release/2023/05/10/2665271/0/en/Alvotech-enters-into-commercialization-agreement-with-Polifarma-for-proposed-biosimilar-to-Eylea-aflibercept.html
https://www.bayer.com/media/en-us/bayer-initiates-phase-iii-study-to-investigate-aflibercept-8-mg-in-retinal-vein-occlusion/
https://www.fiercepharma.com/pharma/roche-genentechs-vabysmo-hot-eyleas-tail-fda-looks-over-new-indication-application
https://www.fiercepharma.com/pharma/sales-fall-again-eylea-regeneron-looks-forward-approval-its-longer-lasting-follow
https://www.globenewswire.com/news-release/2023/04/25/2654401/0/en/New-Vabysmo-data-suggest-greater-retinal-drying-versus-aflibercept-in-nAMD-and-DME.html
https://www.globenewswire.com/news-release/2023/04/20/2650846/0/en/Samsung-Bioepis-to-Present-New-Data-for-SB15-a-proposed-biosimilar-to-Eylea-aflibercept-at-the-2023-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/04/17/2647753/0/en/Aflibercept-8-mg-and-EYLEA-aflibercept-Injection-Presentations-at-ARVO-Provide-New-Insights-into-the-Treatment-of-Serious-Retinal-Diseases.html
https://endpts.com/fda-issues-new-guidance-on-wet-amd-drug-development/
https://www.bayer.com/media/en-us/bayer-submits-aflibercept-8-mg-for-marketing-authorization-in-japan/
https://www.fiercepharma.com/pharma/bayer-acknowledges-slide-eylea-sees-trend-continuing-2023
https://www.fiercepharma.com/pharma/regeneron-eyes-potential-june-approval-high-dose-version-eylea
https://www.globenewswire.com/news-release/2023/02/23/2614121/0/en/Aflibercept-8-mg-BLA-for-Treatment-of-Wet-Age-Related-Macular-Degeneration-and-Diabetic-Macular-Edema-Accepted-for-FDA-Priority-Review.html
https://www.prnewswire.com/news-releases/altos-biologics-a-subsidiary-of-alteogen-completed-patient-enrollment-in-global-phase-3-clinical-trial-of-eylea-biosimilar-in-neovascular-age-related-macular-degeneration-301752666.html
https://www.fiercepharma.com/pharma/roches-edge-vabysmo-cut-and-dried
https://www.fiercepharma.com/pharma/regeneron-bayer-win-another-fda-nod-powerhouse-eylea
https://www.bayer.com/media/en-us/bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu/
https://endpts.com/in-showdown-with-roche-regeneron-gears-up-for-potential-eylea-expansion-amid-covid-decline/
https://endpts.com/in-a-win-for-regeneron-novartis-syringe-for-amd-drug-declared-unpatentable/
https://www.fiercepharma.com/financials/regenerons-roll-eylea-and-dupixent-making-quarter-record-sales
Market Place
Share 
